To study the effect of LCN2 and the LLM ternary complex on tumour progression of ESCC in vivo, as well as the anti‐tumour effect of DFOM in vivo, a xenograft model was used. This evidence concerns the gene LCN2 and esophageal squamous cell carcinoma.